Amgen Inc. (NASDAQ:AMGN) Shares Sold by Courier Capital LLC

Courier Capital LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 6.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 28,729 shares of the medical research company’s stock after selling 1,992 shares during the quarter. Courier Capital LLC’s holdings in Amgen were worth $8,168,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of AMGN. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen in the fourth quarter worth $29,000. United Community Bank acquired a new stake in Amgen in the fourth quarter worth about $29,000. Planned Solutions Inc. bought a new position in Amgen in the 4th quarter valued at about $30,000. Delos Wealth Advisors LLC increased its stake in Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the period. Finally, Hartford Financial Management Inc. raised its position in shares of Amgen by 56.9% during the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after buying an additional 41 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.4 %

NASDAQ AMGN traded down $1.24 during trading on Friday, reaching $312.45. 3,501,088 shares of the company’s stock were exchanged, compared to its average volume of 2,791,167. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a fifty-two week low of $218.44 and a fifty-two week high of $329.72. The company’s fifty day simple moving average is $299.67 and its 200-day simple moving average is $291.67. The firm has a market capitalization of $167.61 billion, a PE ratio of 44.81, a P/E/G ratio of 2.83 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same period last year, the company posted $3.98 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 19.47 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on AMGN. Truist Financial reiterated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. UBS Group lifted their price target on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Raymond James began coverage on Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. Morgan Stanley raised their target price on Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday, May 3rd. Finally, BMO Capital Markets boosted their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $307.35.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.